This article was originally published in The Gray Sheet
Withdraws registration statement filed with the Securities and Exchange Commission for the proposed sale of 2 mil. shares of common stock, citing "unsettled market conditions affecting companies related to the health care industry." The Cincinnati immunodiagnostic firm's chairman, William Motto, said in a July 29 press release that the firm "was unwilling to sell shares at a price level which failed to recognize the company's record of growth and its expectations".
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.